GlassScriptPhysician profile
Todd Lehrfeld
NPI 1235273848
$1,947.34
in general payments reported to CMS, 2019-2025
28 companies · $471 in 2025
The $471 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $249 · 2020: $13.80 · 2021: $167 · 2022: $172 · 2023: $334 · 2024: $540 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,345.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calyxo, INC. | $174.93 | 2025 | Cvac Aspiration System |
| Procept Biorobotics Corporation | $167.42 | 2021 | |
| Daiichi Sankyo INC. | $166.28 | 2022-2025 | Enhertu, Injectafer |
| Boston Scientific Corporation | $143.36 | 2019 | |
| Palette Life Sciences, INC. | $128.10 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $114.30 | 2023-2025 | |
| Pfizer INC. | $107.04 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $103.00 | 2023-2025 | Enhertu, Calquence |
| Merck Sharp & Dohme LLC | $85.33 | 2022-2025 | Keytruda, Lynparza |
| Genmab U.S., INC. | $84.84 | 2024-2025 | Tivdak, Epkinly |
| Tempus Ai, INC | $79.92 | 2024 | Xt Cdx |
| Seagen INC. | $74.92 | 2023 | Tukysa, Adcetris, Padcev |
| Incyte Corporation | $61.67 | 2023-2025 | Jakafi |
| Astellas Pharma US INC | $56.23 | 2023-2025 | Vyloy, Padcev |
| Eisai INC. | $55.98 | 2023-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $52.24 | 2023-2025 | Zoladex, Xermelo |
| Novocure INC. | $49.09 | 2024 | Optune |
| Janssen Biotech, INC. | $45.86 | 2023-2025 | Erleada, Tecvayli |
| Morphosys, US INC. | $30.64 | 2022-2023 | Monjuvi |
| Teleflex LLC | $27.58 | 2025 | Barrigel |
| Takeda Pharmaceuticals U.S.A., INC. | $25.20 | 2024 | Fruzaqla |
| Immunitybio, INC. | $21.07 | 2025 | |
| Aadi Bioscience, INC. | $17.33 | 2023 | Fyarro |
| Sobi, INC | $17.23 | 2024 | |
| Stemline Therapeutics INC. | $15.00 | 2025 | Orserdu |
| Smith+Nephew, INC. | $14.64 | 2019 | |
| Sumitomo Pharma America, INC. | $14.34 | 2024 | Orgovyx |
| Paratek Pharmaceuticals, INC. | $13.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Lehrfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.